TTK Healthcare Ltd. Stock Falls to 52-Week Low of Rs.915

Recent Price Movement and Market Context

On 25 Feb 2026, TTK Healthcare Ltd. touched Rs.915, its lowest level in the past year. This new low comes after three consecutive days of declines, during which the stock lost 1.51% in returns. The day’s performance saw the stock fall by 0.66%, underperforming its sector by 1.31%. Notably, the share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum.

In contrast, the broader market showed resilience on the same day. The Sensex opened higher at 82,530.12, gaining 304.20 points (0.37%), and was trading near 82,281.24, a modest 0.07% increase. The Sensex remains 4.71% below its 52-week high of 86,159.02, with mega-cap stocks leading the gains. However, TTK Healthcare’s performance diverges sharply from this positive market backdrop.

Long-Term Performance and Valuation Concerns

Over the past year, TTK Healthcare has delivered a negative return of 22.80%, significantly lagging behind the Sensex’s positive 10.33% gain. The stock’s 52-week high was Rs.1,402, indicating a substantial decline of approximately 34.7% from that peak. This underperformance extends beyond the last year, with the stock also trailing the BSE500 index over the last three years, one year, and three months.

The company’s long-term growth metrics have been subdued. Net sales have grown at an annualised rate of 6.99% over the past five years, while operating profit has increased at 15.42% annually. These figures suggest modest expansion relative to peers in the diversified sector. The company’s Mojo Score stands at 37.0, with a Mojo Grade of Sell, downgraded from Hold on 21 Jul 2025, reflecting deteriorated fundamentals and market sentiment.

Financial Metrics Highlighting Current Challenges

TTK Healthcare’s recent financial disclosures reveal several areas of concern. The company reported flat results in the December 2025 quarter, indicating limited near-term growth momentum. Cash and cash equivalents at the half-year mark stood at Rs.600.89 crores, the lowest level recorded in recent periods, which may constrain liquidity flexibility.

The debtor turnover ratio for the half-year was 7.40 times, also the lowest in recent history, suggesting slower collections and potential working capital pressures. Additionally, non-operating income accounted for 80.43% of profit before tax in the latest quarter, indicating that core business profitability remains subdued.

Despite its sizeable market presence, domestic mutual funds hold a minimal stake of just 0.01% in TTK Healthcare. Given their capacity for detailed research and due diligence, this limited exposure may reflect cautious positioning towards the stock’s current valuation and business outlook.

Balance Sheet and Valuation Overview

The company maintains a low average debt-to-equity ratio of zero, indicating a debt-free balance sheet which is a positive aspect in terms of financial stability. Return on equity (ROE) stands at 6.5%, a modest figure that aligns with the company’s subdued growth profile.

Valuation metrics present a mixed picture. The stock trades at a price-to-book value of 1.2, which is considered attractive relative to some peers. However, it is priced at a premium compared to the average historical valuations of its sector counterparts. The price-to-earnings-to-growth (PEG) ratio is notably high at 7.9, reflecting a disconnect between earnings growth and market price.

Profit growth over the past year has been limited, with a rise of only 2.4%, further underscoring the challenges in generating robust earnings expansion despite the stock’s valuation.

Summary of Performance Relative to Market Benchmarks

TTK Healthcare’s stock performance has been consistently below market benchmarks. The 1-year return of -22.80% contrasts sharply with the Sensex’s 10.33% gain over the same period. The Sensex itself is trading below its 50-day moving average but remains above its 200-day moving average, indicating a generally positive medium-term trend for the broader market. In comparison, TTK Healthcare’s share price is well below all major moving averages, highlighting its relative weakness.

The stock’s underperformance extends to the BSE500 index, where it has lagged over the last three years, one year, and three months. This persistent underperformance reflects both the company’s financial results and market sentiment towards its sector and business model.

Conclusion

TTK Healthcare Ltd.’s decline to a 52-week low of Rs.915 is the culmination of subdued sales growth, limited profit expansion, and valuation concerns. The stock’s underperformance relative to sector peers and broader market indices underscores the challenges faced by the company in delivering sustained shareholder returns. While the company benefits from a debt-free balance sheet and an attractive price-to-book ratio, its modest ROE and high PEG ratio highlight the cautious stance reflected in its current market valuation.

Investors and market participants will continue to monitor the company’s financial disclosures and market movements closely, given the stock’s recent trend and fundamental profile.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →